A Houston software company has announced the five early-stage startups it will be supporting through its new venture studio. Photo via Getty Images

A Houston-based technology consultancy with a portfolio of Fortune 500 clients has announced the five companies it will be supporting in its new startup studio.

Softeq Development Corporation announced its inaugural cohort for the Softeq Venture Studio. The program, which will be offered quarterly for four to six startups each cohort, is geared at helping its resident startups quickly develop their technology and build their businesses.

"Historically, most tech startups had a founder with development skills. However, we're now seeing more and more business people, doctors, and other professionals start companies, and they need a strong engineering partner to develop their products," says Christopher A. Howard, Softeq founder and CEO, in a news release. "We take it several steps further with the Venture Studio providing technology business consulting, development services, and much-needed cash. We're a vested partner, so we also help secure follow-on funding for continued growth."

Christopher A. Howard is the founder and CEO of Softeq. Photo courtesy of Softeq

The group of startups are from the Bay Area, New York, Boston, and Houston and represents several industries, including sports tech, med-tech, and lifestyle tech. The founders of all five of the early-stage startups will work in Houston from October through December in their provided office space at FUSE in CITYCENTRE near the Softeq corporate headquarters in the Energy Corridor. Participating companies each receive $100,000 in cash and development services in exchange for a small piece of equity in their company, per the release. Serial entrepreneur Billy Grandy will lead the program.

"Most early-stage accelerators focus on the business aspects of a startup," says Grandy. "Adding the enterprise-focused development resources of Softeq helps startups de-risk the effort and puts future investors at ease. Furthermore, Houston's rapidly growing innovation ecosystem and access to an active investment community and tech-forward business leaders make this city a perfect venue for startups."

The companies selected for the fall cohort are:

  • Atlas Coaching is a marketplace to connect female sports celebrities, pros, and coaches with fans looking to improve their game and receive digital training.
  • FitLift improves strength training techniques and reduces injuries through a mobile app and wearable device that tracks precise motion and provides feedback.
  • GetScouted aims to provide a verifiable source of athletes' performance and statistics to coaches and scouts using biometric analysis and analytics.
  • Home Outside is democratizing landscape design by making it simple, affordable, automated, easy to visualize, and integrated through AI and 1-click ordering.
  • Orcana is a medical technology startup utilizing augmented reality and AI to provide 24/7 remote support for operating rooms to reps, surgeons, and surgical teams.

The applications are already open for the winter cohort, which will be held mid-January through March of 2022. Companies can apply until December 11, 2021, at www.softeq.com/venture-studio.

Softeq also announced its Innovation Lab last year. The lab is in partnership with the Massachusetts Institute of Technology's Integrated Design and Management program and Massachusetts-based Boundless Technology and is directed at helping enterprise companies collaborate on the technologies of tomorrow.

Howard recently discussed with InnovationMap his passion for cultivating technology innovation in Houston on a recent episode of the Houston Innovators Podcast. Listen to it below.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston space company lands latest NASA deal to advance lunar logistics

To The Moon

Houston-based space exploration, infrastructure, and services company Intuitive Machines has secured about $2.5 million from NASA to study challenges related to carrying cargo on the company’s lunar lander and hauling cargo on the moon. The lander will be used for NASA’s Artemis missions to the moon and eventually to Mars.

“Intuitive Machines has been methodically working on executing lunar delivery, data transmission, and infrastructure service missions, making us uniquely positioned to provide strategies and concepts that may shape lunar logistics and mobility solutions for the Artemis generation,” Intuitive Machines CEO Steve Altemus says in a news release.

“We look forward to bringing our proven expertise together to deliver innovative solutions that establish capabilities on the [moon] and place deeper exploration within reach.”

Intuitive Machines will soon launch its lunar lander on a SpaceX Falcon 9 rocket to deliver NASA technology and science projects, along with commercial payloads, to the moon’s Mons Mouton plateau. Lift-off will happen at NASA’s Kennedy Space Center in Florida within a launch window that starts in late February. It’ll be the lander’s second trip to the moon.

In September, Intuitive Machines landed a deal with NASA that could be worth more than $4.8 billion.

Under the contract, Intuitive Machines will supply communication and navigation services for missions in the “near space” region, which extends from the earth’s surface to beyond the moon.

The five-year deal includes an option to add five years to the contract. The initial round of NASA funding runs through September 2029.

Play it back: Houston home tech startup begins 2025 with fresh funding

HOUSTON INNOVATORS PODCAST EPISODE 272

One of the dozen or so Houston startups kicking of the new year with fresh funding is SmartAC.com, a company that's designed a platform that enables contractors in the HVAC and plumbing industries to monitor, manage, and optimize their maintenance memberships through advanced sensors, AI-driven diagnostics, and proactive alerts.

Last month, the SmartAC.com raised a follow-on round with support from local investor Mercury to continue growth and expansion of the product, which has evolved on many ways since the company launched in 2020, emerging from stealth with $10 million raised in a series A. In a May 2023 interview for the Houston Innovators Podcast, Founder and CEO Josh Teekell explained how he embraced the power of a pivot.

The company's sensors can monitor all aspects of air conditioning units and report back any issues, meaning homeowners have quicker and less costly repairs. While SmartAC.com started with providing the service and tech to homeowners directly, Teekell says he's had a greater interest in working with plumbers and HVAC companies who then deploy the technology to their customers.

"It became quite evident that homeowners don't care about air conditioning really at all until their system breaks," Teekell says on the show. "The technology is really built around giving those contractors as another way to gain a customer relationship and keep it."

Revisit the podcast episode below where Teekell talks about SmartAC.com's last raise.

SmartAC.com's previous round in 2023 — a $22 million series B — was used grow its team that goes out to deploy the technology and train the contractors on the platform.

"We've been very fortunate to get some of the biggest names in Houston on our cap table," Teekell says in the May 2023 conversation. "Since we're raising a bunch of money locally, everyone understands what a pain air conditioning can be."

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.